A number of firms have modified their ratings and price targets on shares of Sunesis Pharmaceuticals (NASDAQ: SNSS) recently:

  • 9/13/2016 – Sunesis Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Sunesis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. It has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics. It is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies. “
  • 9/12/2016 – Sunesis Pharmaceuticals had its “buy” rating reaffirmed by analysts at Cantor Fitzgerald.
  • 9/12/2016 – Sunesis Pharmaceuticals had its “hold” rating reaffirmed by analysts at Cowen and Company.
  • 9/7/2016 – Sunesis Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Sunesis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. It has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics. It is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies. “
  • 8/31/2016 – Sunesis Pharmaceuticals was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Sunesis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. It has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics. It is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies. “
  • 8/24/2016 – Sunesis Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Sunesis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. It has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics. It is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies. “
  • 7/29/2016 – Sunesis Pharmaceuticals was upgraded by analysts at Wells Fargo & Co. from a “market perform” rating to an “outperform” rating.
  • 7/29/2016 – Sunesis Pharmaceuticals had its “market perform” rating reaffirmed by analysts at Cowen and Company. They wrote, “Sunesis intends to respond to the EMA’s Day 120 questions on vosaroxin for r/r AML.””

Shares of Sunesis Pharmaceuticals Inc. (NASDAQ:SNSS) opened at 4.38 on Thursday. Sunesis Pharmaceuticals Inc. has a 52-week low of $2.64 and a 52-week high of $6.96. The stock’s 50 day moving average is $4.46 and its 200-day moving average is $3.54. The firm’s market cap is $63.52 million.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/22/analysts-recent-ratings-updates-for-sunesis-pharmaceuticals-snss.html

Sunesis Pharmaceuticals (NASDAQ:SNSS) last released its earnings results on Friday, July 29th. The biopharmaceutical company reported ($0.12) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.10) by $0.02. Sunesis Pharmaceuticals had a negative net margin of 1,503.34% and a negative return on equity of 806.43%. The business had revenue of $0.60 million for the quarter, compared to analysts’ expectations of $0.70 million. During the same period last year, the firm earned ($0.15) EPS. The company’s revenue was down 33.3% compared to the same quarter last year. Equities analysts anticipate that Sunesis Pharmaceuticals Inc. will post ($2.65) earnings per share for the current fiscal year.

Sunesis Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZO (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia (AML).

5 Day Chart for NASDAQ:SNSS

Receive News & Ratings for Sunesis Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.